Chin-Hsiao Tseng. (2023). Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients. MDPI AG.
Chicago Style (17th ed.) CitationChin-Hsiao Tseng. Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients. MDPI AG, 2023.
MLA (9th ed.) CitationChin-Hsiao Tseng. Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients. MDPI AG, 2023.
Warning: These citations may not always be 100% accurate.